Risk of primary infection and reinfection with respiratory syncytial virus
- PMID: 3706232
- DOI: 10.1001/archpedi.1986.02140200053026
Risk of primary infection and reinfection with respiratory syncytial virus
Abstract
Respiratory syncytial virus is the most important cause of serious lower respiratory tract infection in children. For children followed up from birth in the Houston Family Study, the infection rate was 68.8/100 children less than 12 months of age and 82.6/100 during the second year of life. Virtually all children had been infected at least once by 24 months of age, and about one half had experienced two infections. Although lower respiratory tract disease (LRD) was common (22.4/100 during year 1 and 13.0/100 during year 2), most children had only one LRD illness. The risk of reinfection was inversely related to the level of neutralizing antibodies in the serum. Reinfection illnesses were generally mild, and risk of reinfection decreased to only 33.3/100 during year 4. Studies of children with LRD and surveys of hospitalizations provide the basis for an estimate of the number of children hospitalized each year during the respiratory syncytial virus epidemics. Almost 100,000 children in the United States experience an illness of sufficient severity to require hospitalization.
Similar articles
-
Influenza in children. Relationship to other respiratory agents.JAMA. 1980 Apr 4;243(13):1345-9. doi: 10.1001/jama.243.13.1345. JAMA. 1980. PMID: 6244421
-
Respiratory syncytial virus infection in children with bronchopulmonary dysplasia.Pediatrics. 1988 Aug;82(2):199-203. Pediatrics. 1988. PMID: 3399292
-
Detection, pathogenesis, and therapy of respiratory syncytial virus infections.Clin Microbiol Rev. 1988 Jan;1(1):27-39. doi: 10.1128/CMR.1.1.27. Clin Microbiol Rev. 1988. PMID: 3060243 Free PMC article. Review.
-
Pulmonary infections with respiratory syncytial virus and the parainfluenza viruses.Semin Respir Infect. 1987 Jun;2(2):112-21. Semin Respir Infect. 1987. PMID: 2827280 Review.
-
The Seattle Virus Watch. VI. Observations of infections with and illness due to parainfluenza, mumps and respiratory syncytial viruses and Mycoplasma pneumoniae.Am J Epidemiol. 1975 Jun;101(6):532-51. doi: 10.1093/oxfordjournals.aje.a112125. Am J Epidemiol. 1975. PMID: 168766
Cited by
-
Cost-Effectiveness Analysis of Maternal Respiratory Syncytial Virus Vaccine in Protecting Infants from RSV Infection in Japan.Infect Dis Ther. 2024 Jul;13(7):1665-1682. doi: 10.1007/s40121-024-01000-6. Epub 2024 Jun 5. Infect Dis Ther. 2024. PMID: 38834858 Free PMC article.
-
Immunogenicity and safety of Ad26.RSV.preF/RSV preF protein vaccine at predicted intermediate- and end-of-shelf-life as an evaluation of potency throughout shelf life.Hum Vaccin Immunother. 2024 Dec 31;20(1):2344970. doi: 10.1080/21645515.2024.2344970. Epub 2024 May 23. Hum Vaccin Immunother. 2024. PMID: 38783590 Free PMC article. Clinical Trial.
-
Modelling respiratory syncytial virus age-specific risk of hospitalisation in term and preterm infants.BMC Infect Dis. 2024 May 21;24(1):510. doi: 10.1186/s12879-024-09400-2. BMC Infect Dis. 2024. PMID: 38773455 Free PMC article.
-
Identification of distinct genotypes in circulating RSV A strains based on variants on the virus replication-associated genes.bioRxiv [Preprint]. 2024 Apr 23:2024.04.22.590570. doi: 10.1101/2024.04.22.590570. bioRxiv. 2024. PMID: 38712045 Free PMC article. Preprint.
-
Computational Insights into the Interaction of the Conserved Cysteine-Noose Domain of the Human Respiratory Syncytial Virus G Protein with the Canonical Fractalkine Binding site of Transmembrane Receptor CX3CR1 Isoforms.Membranes (Basel). 2024 Apr 4;14(4):84. doi: 10.3390/membranes14040084. Membranes (Basel). 2024. PMID: 38668112 Free PMC article.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Other Literature Sources